What each measures

For typical patients with normal-sized LDL particles, the two correlate well. For patients with abnormal particle sizes, they can diverge.

When they diverge

LDL-C may underestimate risk when:

LDL-C may overestimate risk when:

Small dense LDL

Small dense LDL particles are more atherogenic per particle than large LDL because:

Patients with small dense LDL pattern often have insulin resistance, high triglycerides, low HDL, the "metabolic syndrome" phenotype.

Metabolic pattern

Classic metabolic syndrome lipid pattern:

Standard panel says "lipids okay" if you only look at LDL-C. ApoB or LDL-P testing reveals the elevated risk.

LDL-P vs ApoB

Both measure particles. ApoB captures all atherogenic particles (LDL, VLDL, IDL, Lp(a)). LDL-P specifically counts LDL. ApoB is more widely available and similarly predictive of cardiovascular events. For most patients, ApoB is sufficient.

LDL-P (via NMR spectroscopy) gives more particle detail but is less commonly available.

The clinical insight: Don't trust LDL-C alone in patients with metabolic syndrome features. Add ApoB or LDL-P. Patients with normal LDL-C and elevated ApoB are common, and have higher cardiovascular risk than LDL-C alone suggests.

Bottom line

LDL-C and LDL-P measure different things. They diverge most in metabolic dysfunction. Particle count better predicts cardiovascular risk than cholesterol amount. ApoB or LDL-P provides this; standard panels don't.

Particles
drive atherosclerosis, not cholesterol amount
Common
discordance in metabolic syndrome
ApoB or LDL-P
recommended addition to lipid panel